Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

On February 7, 2023 Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., reported that they are now doing business as Perspective Therapeutics, Inc., along with a new brand identity effective immediately (Press release, Viewpoint Molecular Targeting, FEB 7, 2023, https://viewpointmt.com/isoray-inc-and-viewpoint-molecular-targeting-inc-announce-name-change-to-perspective-therapeutics-inc/ [SID1234626969]). Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its Certificate of Incorporation as soon as possible.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Post-merger rebranding highlights include:

New tagline: "Treating cancers from the inside out"
New corporate website View Source
New NYSE American stock ticker symbol to be CATX, effective February 21, 2023
"We believe that Perspective Therapeutics truly reflects our potential to transform the field of precision oncology medicine and the outcome of early-stage cancers through the advancement of radiopharmaceuticals," said Perspective Therapeutics, Inc. CEO Thijs Spoor. "On behalf of Perspective Therapeutics board of directors, employees and myself we look forward to bringing the Company’s focus, as well as our commercial and strategic pipeline development objectives to life."

The Company currently trades on the NYSE American as Isoray, Inc. under ticker symbol ISR which will change to Perspective Therapeutics, Inc. with the ticker symbol of CATX on February 21, 2023.

Oppenheimer & Co. acted as Isoray’s financial advisor for the merger transaction and Gallagher & Kennedy, P.A. served as Isoray’s legal counsel. Sichenzia Ross Ference, LLP acted as Viewpoint’s legal counsel.